Beactica Therapeutics - Precision Oncology
2024年2月14日 · Beactica Therapeutics is a precision oncology company developing novel, life-saving small molecule therapeutics to treat genetically defined cancers with significant unmet …
仅显示来自 beactica.com 的搜索结果About us Öppna
Beactica's vision is to create novel medicines that improve the prospects for …
Science Öppna
Degraders of TEAD Transcription Factors Based on Interface 3 Binders, American …
Partnering Öppna
NCATS is given access to proprietary targeted degraders of TEAD from …
Investors
Beactica Therapeutics is a specialist precision oncology company, founded in …
Resources & Media Öppna
Beactica Therapeutics’ TEAD …Contact
Beactica Therapeutics AB. Uppsala Business Park. Rapsgatan 7. 754 50 …
Beactica Therapeutics’ TEAD programme selected for late-breaking ...
2024年2月14日 · Beactica Therapeutics AB, the Swedish precision oncology company, today announced that its TEAD programme has been selected for a late-breaking presentation at the …
Beactica Therapeutics announces collaboration with the National …
2023年9月26日 · Beactica Therapeutics AB, the Swedish precision oncology company, today announced that it has entered into a research collaboration agreement with the National …
TEAD 抑制剂 (Beactica) (TEAD inhibitors (Beactica)) - 药物靶 …
TEAD 抑制剂 (Beactica): 一种TEAD 抑制剂药物，由Beactica Therapeutics AB (Beactica Therapeutics AB)公司最早进行研发，目前全球最高研发状态为临床前，作用机制: TEAD 抑制 …
Beactica Therapeutics AB (Beactica Therapeutics AB) - 药物管线_专 …
根据协议，NCATS将使用Beactica专有的TEAD靶向降解剂，在疾病相关临床前模型中评价其功效。NCATS还将使用约3000种针对肿瘤的机械注释药物进行高通量药物组合筛选，系统地展现 …
Beactica Therapeutics' TEAD programme selected for late-breaking ...
2024年2月14日 · Beactica Therapeutics AB, the Swedish precision oncology company, today announced that its TEAD programme has been selected for a late-breaking presentation at the …
- 其他用户还问了以下问题
Beactica Therapeutics' TEAD programme selected for late-breaking ...
2024年2月14日 · The presentation will include new positive results from studies with novel proteolysis-targeting degraders of TEAD based on interface 3-binding ligands under …
Beactica Therapeutics announces collaboration with the National …
2023年9月26日 · Under the agreement, NCATS will gain access to proprietary targeted degraders of TEAD from Beactica to evaluate their efficacy in disease-relevant preclinical models.
Beactica Therapeutics' TEAD programme selected for late
2024年2月14日 · The presentation will include new positive results from studies with novel proteolysis-targeting degraders of TEAD based on interface 3-binding ligands under …
TEAD modulators/degraders were evaluated against TEAD-dependent mesothelioma cell lines and TEAD-independent uveal melanoma cell lines in a CellTiter-Glo assay after 48 h incubation.
Beactica Tead 的相关搜索
